Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of β-tubulin III and Survivin in Advance Stage Breast Cancer Correlates with Chemotheraputic Effects of Docetaxel

  • Yuan, Shao-Fei (Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College) ;
  • Zhu, Lin-Jia (Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College) ;
  • Zheng, Wei-E (Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College) ;
  • Chen, Hua (Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College) ;
  • Wu, Li-Li (Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College) ;
  • Zhang, Wu (Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College) ;
  • Sun, Hong-Yu (Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College) ;
  • Chen, Wen-Jun (Cancer Center, the Third Affiliated Hospital, Wenzhou Medical College)
  • Published : 2012.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Aims: To investigate the relationship between the expression of ${\beta}$-tubulin III and survivin in advanced breast cancers and chemotherapeutic effects of docetaxel. Methods: Clinical pathological data of 74 patients with advanced breast cancer were retrospectively analyzed after docetaxel chemotherapy. Expression of ${\beta}$-tubulin III and survivin was assessed by immunohistochemistry and analyzed with reference to therapeutical and adverse effects of docetaxel. Results: The positive expression rate of ${\beta}$-tubulin III was 38.1% (32/84), while that of survivin was 76.2% (64/84). The effective rate (complete response + partial response) was 52.4%. That for patients with the positive expression of ${\beta}$-tubulin III or/and survivin was significantly lower than for those with negative expression (P<0.05). There were significant differences in the non-progression of median diseases, 1-year and 2-year survival rates of between the patients with positive and negative expression (P<0.05). The main side effects were myelosuppression, alimentary canal response and alopecie, no differences being observed between groups. Conclusions: The combined detection of ${\beta}$-tubulin III and survivin is a predictive index for chemotherapy effects of docetaxel in metastatic breast cancer.

Keywords

References

  1. Altieri DC (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer, 3, 462.
  2. Banerjee A (2002). Increased levels of tyrosinated alpha-beta (III)-and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun, 293, 598-601. https://doi.org/10.1016/S0006-291X(02)00269-3
  3. Biganzoli L, Minisini A, Aapro M, et a1 (2004). Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol, 16, 37-41. https://doi.org/10.1097/00001703-200402000-00008
  4. Campone M, Blasinska-Morawiec M, Tekiela A, et a1 (2009). Phase II study of vinorelbine (altemating intravenous and oral)in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol, 63, 937-43. https://doi.org/10.1007/s00280-008-0816-5
  5. Grisko T,Williams A, Turkson J, et al (2006). Persistent activation of state signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res, 12, 11-9. https://doi.org/10.1158/1078-0432.CCR-04-1752
  6. Jones SE, Erban J, Ovemoyer B, et a1(2005). Randomized phaseⅢ study of docetaxel compared with paclitaxel in metastatic breast cancer. Clin Oncol, 23, 5542-51. https://doi.org/10.1200/JCO.2005.02.027
  7. Kappler M, Rot S, Taubert H, et al (2007). The effects of knockdown of wild-type survivin, survivin-2B or survivindelta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther, 14, 994-1001. https://doi.org/10.1038/sj.cgt.7701090
  8. Khan MA, Carducci MA, Partin AW (2003). The evolving role of docetaxel in the management of androgen independment prostate cancer. J Urol, 170, 1709- 16. https://doi.org/10.1097/01.ju.0000088787.95124.4b
  9. Ranganathan S, Benetatos CA, Colarusso PJ, et al (2008). Altered-tubulin isotype expression in paclitaxel resistant human prostate carcinoma cells. Br J Cancer, 77, 562-6. https://doi.org/10.1038/bjc.1998.91
  10. Wang W Ouyang X, Zhang X (2006). Therapeutic effects of survivin and bcl-2 gene combined with antisense oligodeoxynucleotide on human breast cancer transplanted subcutaneously in nude mice. Chinese J Clin Pharmacol Therapeutics, 11, 1164-7.

Cited by

  1. Ani-survivin DNAzymes Inhibit Cell Proliferation and Migration in Breast Cancer Cell Line MCF-7 vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6233
  2. βIII-Tubulin: biomarker of taxane resistance or drug target? vol.17, pp.4, 2013, https://doi.org/10.1517/14728222.2013.766170
  3. Microtubule-Associated Protein Tau, α-Tubulin and βIII-Tubulin Expression in Breast Cancer vol.47, pp.6, 2013, https://doi.org/10.4132/KoreanJPathol.2013.47.6.534
  4. Lack of Relation of Survivin Gene Expression with Survival and Surgical Prognostic Factors in Endometrial Carcinoma Patients vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6905
  5. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients vol.73, pp.1, 2014, https://doi.org/10.1007/s00280-013-2315-6
  6. Use of TUBB3 for patient stratification and prognosis in lung cancer vol.4, pp.2, 2015, https://doi.org/10.2217/lmt.15.6
  7. Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin vol.34, pp.1, 2016, https://doi.org/10.1007/s10637-015-0315-6
  8. Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers vol.39, pp.10, 2017, https://doi.org/10.1177/1010428317712166
  9. High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer vol.11, pp.3, 2016, https://doi.org/10.3892/ol.2016.4206